Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Melanoma 1

Interventions

trametinib 2fludarabine 2thymoglobulin 1talimogene laherparepvec 1fludarabine phosphate 1dabrafenib 1abemaciclib 1Waiting Lists 1Rituximab 1Photochemotherapy 1Melphalan 1Liquid Biopsy 1Levetiracetam 1Injections 1Cytarabine 1Cyclophosphamide 1Busulfan 1Azacitidine 1Aminolevulinic Acid 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neurofibromatosis 1 × talimogene laherparepvec × Clear all
NCT07102394 2026-05-08

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Johns Hopkins University

Phase 1 Recruiting
10 enrolled
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡